Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DERMATOLOGY / CLINICAL RESEARCH
Interplay between IL-17 family members and angiogenic cytokines in subjects with systemic sclerosis
1
Department of Dermatology and Venereology, Medical University of Lodz, Poland
2
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland
3
University of Economic and Human Sciences, Warsaw, Poland
Submission date: 2020-02-09
Final revision date: 2020-09-16
Acceptance date: 2020-10-03
Online publication date: 2021-03-21
Publication date: 2026-08-28
Corresponding author
Ewa Robak
Department of Dermatology and Venereology Medical University of Lodz 1 Haller’s Square 90-647 Lodz, Poland Phone: +48 42 6867981 Fax: +48 42 6884565
Department of Dermatology and Venereology Medical University of Lodz 1 Haller’s Square 90-647 Lodz, Poland Phone: +48 42 6867981 Fax: +48 42 6884565
Arch Med Sci 2026;22(4):2220-2230
KEYWORDS
vascular endothelial growth factor Aplacenta growth factorhepatocyte growth factorangiogenesis inducing agents
TOPICS
ABSTRACT
Introduction:
Systemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease characterized by immune system activation, vasculopathy, and collagen accumulation. Despite progressive fibrosis of the vasculature, compensatory angiogenesis is impaired. The cause of the shift towards anti-angiogenesis observed in SSc is unknown. The interleukin-17 (IL-17) cytokine family participates in the pathogenesis of SSc and angiogenesis.
Material and methods:
Our study aimed to evaluate levels and find relationships between the levels of proangiogenic cytokines and cytokines from the IL-17 family in 42 SSc subjects and 20 healthy controls. Vascular endothelial growth factor (VEGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), transforming growth factor β1 (TGF-β1), granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-17A, IL-17B, IL-17E and IL-17F were quantified in the sera of all participants by ELISA sandwich kits.
Results:
Significantly higher mean concentrations of PlGF compared to the control mean value (19.3 pg/ml in the SSc group vs. 11.4 pg/ml in the control group; p < 0.001) and of HGF (1931 pg/ml in the SSc group vs. 1483 pg/ml in controls; p < 0.05) were observed. Mean serum TGF-β1 level was also significantly lower in the SSc group (781 pg/ml) than in controls (35991 pg/ml; p < 0.001). Among the IL-17 family, significantly higher mean concentrations of IL-17B (67.0 pg/ml vs. 2.6 pg/ml in controls; p < 0.001), IL-17E (8.0 pg/ml vs. 0.64 pg/ml in controls; p < 0.001) and IL-17F (0.42 pg/ml vs. 0.0 pg/ml in controls; p < 0.01) were detected. Serum concentrations of HGF and PlGF correlated with the concentrations of IL17A, IL-17B, and IL-17E.
Conclusions:
Our findings indicate that selected cytokines from the IL-17 family participate in the pathogenesis of SSc and are responsible for the vascular abnormalities associated with this disorder.
Systemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease characterized by immune system activation, vasculopathy, and collagen accumulation. Despite progressive fibrosis of the vasculature, compensatory angiogenesis is impaired. The cause of the shift towards anti-angiogenesis observed in SSc is unknown. The interleukin-17 (IL-17) cytokine family participates in the pathogenesis of SSc and angiogenesis.
Material and methods:
Our study aimed to evaluate levels and find relationships between the levels of proangiogenic cytokines and cytokines from the IL-17 family in 42 SSc subjects and 20 healthy controls. Vascular endothelial growth factor (VEGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), transforming growth factor β1 (TGF-β1), granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-17A, IL-17B, IL-17E and IL-17F were quantified in the sera of all participants by ELISA sandwich kits.
Results:
Significantly higher mean concentrations of PlGF compared to the control mean value (19.3 pg/ml in the SSc group vs. 11.4 pg/ml in the control group; p < 0.001) and of HGF (1931 pg/ml in the SSc group vs. 1483 pg/ml in controls; p < 0.05) were observed. Mean serum TGF-β1 level was also significantly lower in the SSc group (781 pg/ml) than in controls (35991 pg/ml; p < 0.001). Among the IL-17 family, significantly higher mean concentrations of IL-17B (67.0 pg/ml vs. 2.6 pg/ml in controls; p < 0.001), IL-17E (8.0 pg/ml vs. 0.64 pg/ml in controls; p < 0.001) and IL-17F (0.42 pg/ml vs. 0.0 pg/ml in controls; p < 0.01) were detected. Serum concentrations of HGF and PlGF correlated with the concentrations of IL17A, IL-17B, and IL-17E.
Conclusions:
Our findings indicate that selected cytokines from the IL-17 family participate in the pathogenesis of SSc and are responsible for the vascular abnormalities associated with this disorder.
REFERENCES (69)
1.
Barsotti S, Mattaliano V, d’Ascanio A, et al. Systemic sclerosis chronic ulcers: preliminary results of treatment with allogenic skin grafting in a cohort of Italian patients. Int Wound J 2016; 13: 1050-1.
2.
Sacilotto N, Chouliaras KM, Nikitenko LL, et al. MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes Dev 2016; 30: 2297-309.
3.
Vallée A, Guillevin R, Vallée JN. Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/-catenin pathway in gliomas. Rev Neurosci 2018; 29: 71-91.
4.
Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6: 1102-3.
5.
Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-54.
6.
Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008; 41: 278-86.
7.
Kitamura K, Iwanami A, Nakamura M. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res 2007; 85: 2332-42.
8.
Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009; 219: 449-58.
9.
Zhao J, Chen L, Shu B. Granulocyte/macrophage colony-stimulating factor influences angiogenesis by regulating the coordinated expression of VEGF and the Ang/Tie system. PLoS One 2014; 9: e92691.
10.
Liu G, Wu H, Chen L. Effects of interleukin-17 on human retinal vascular endothelial cell capillary tube formation in vitro. Mol Med Rep 2017; 16: 865-72.
11.
Li Y, Zhou Y. Interleukin-17: the role for pathological angiogenesis in ocular neovascular diseases. Tohoku J Exp Med 2019; 247: 87-98.
12.
Xing X, Yang J, Yang X. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One 2013; 8: e85032.
13.
Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 2012; 32: 2653-60.
14.
Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009; 4: e5903.
15.
Numasaki M, Fukushi J, Ono M. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-7.
16.
Starnes T, Robertson MJ, Sledge G, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001; 167: 4137-40.
17.
Xie Y, Sheng W, Xiang J, Ye Z, Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest 2010; 28: 598-607.
18.
Sanders AJ, Guo X, Mason MD, Jiang WG. IL-17B can impact on endothelial cellular traits linked to tumour angiogenesis. J Oncol 2010; 2010: 817375.
19.
Tong Z, Yang XO, Yan H, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012; 7: e34959.
20.
Honorati MC, Neri S, Cattini L, Facchini, A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006; 14: 345-52.
21.
Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008; 41: 84-91.
22.
Chung AS, Wu X, Zhuang G, et al. An interleukin17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19: 1114-23.
23.
Razia S, Noveiryc BB, Keshavarz-Fathia M, Rezae N. IL-17 and colorectal cancer: from carcinogenesis to treatment. Cytokine 2019; 116: 7-12.
24.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
25.
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
26.
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
27.
Kahaleh MB, Suttany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin score method. Clin Exp Rheumatol 1986; 4: 367-9.
28.
Robak E, Gerlicz Kowalczuk Z, Dziankowska-Bartkowiak B, Woźniacka A, Bogaczewicz J. Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci 2019; 15: 706-12.
29.
Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, et al. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 2014; 17: 664-70.
30.
Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
31.
Simonian PL, Roark CL, Wehrmann F, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 2009; 182: 657-65.
32.
Okamoto Y, Hasegawa M, Matsushita T, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 2012; 64: 3726-35.
33.
Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013; 15: R151.
34.
Odorisio T, Cianfarani F, Failla CM, Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci 2006; 41: 11-9.
35.
Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 22: 1876-83.
36.
Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002; 62: 2749-52.
37.
Avouac J, Meune C, Ruiz B, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 2012; 71: 394-9.
38.
Hamaguchi Y, Hasegawa M, Tanaka C, et al. Elevated serum placenta growth factor (PlGF) levels in patients with systemic sclerosis: a possible role in the development of skin but not lung fibrosis. J Dermatol Sci 2010; 58: 229-31.
39.
Mundim GJ, Paschoini MC, Araujo E Jr, Da Silva Costa F, Rodrigues V Jr. Assessment of angiogenesis modulators in pregnant women with pre-eclampsia: a case-control study. Arch Gynecol Obstet 2016; 293: 369-75.
40.
Robak E, Kulczycka-Siennicka L, Gerlicz Z, Kierstan M, Korycka-Wolowiec A, Sysa-Jedrzejowska A. Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. Eur Cytokine Netw 2013; 24: 60-8.
41.
Broughton SE, Dhagat U, Hercus TR, et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 2012; 250: 277-302.
42.
Hu X, Sun H, Han C, Wang X, Yu W. Topically applied rhGM-CSF for the wound healing: a systematic review. Burns 2011; 37: 729-41.
43.
Postiglione L, Ladogana P, Montagnani S, et al. Effect of granulocyte macrophage-colony stimulating factor on extracellular matrix deposition by dermal fibroblasts from patients with scleroderma. J Rheumatol 2005; 32: 656-64.
44.
Postiglione L, Montagnani S, Riccio A, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol 2002; 29: 94-101.
45.
Zhu HL, DU Q, Chen WL, Zuo XX, Li QZ, Liu SJ. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms]. Beijing Da Xue Xue Bao Yi Xue Ban 2019; 51: 716-22.
46.
Laan M, Prause O, Miyamoto M, et al. A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 and TNF-alpha. Eur Respir J 2003; 21: 387-93.
47.
Wu L, Ong S, Talor MV, et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med 2014; 211: 1449-64.
48.
Hirigoyen D, Burgos PI, Mezzano V, et al. Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther 2015; 17: 332.
49.
Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular-endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011; 109: e14-26.
50.
Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-7.
51.
Zhou Y, Hou W, Xu K. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol 2015; 76: 22-9.
52.
Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007; 3: 682-3.
53.
Gregory LG, Jones CP, Walker SA, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 2013; 68: 82-90.
54.
Hams E, Armstrong ME, Barlow JL, et al. IL25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci USA 2014; 111: 367-72.
55.
Lonati PA, Brembilla NC, Montanari E, et al. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS One 2014; 9: e105008.
56.
Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-62.
57.
Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013; 62: 175-82.
58.
Kang Z, Swaidani S, Yin W, et al. Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(−)c-Kit(+) innate cell population. Immunity 2012; 36: 821-33.
59.
Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464: 1367-70.
60.
Saenz SA, Siracusa MC, Perrigoue JG, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010; 464: 1362-6.
61.
Shi Y, Ullrich SJ, Zhang J, et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000; 275: 19167-76.
62.
Li H, Chen J, Huang A, Stinson J. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000; 97: 773-8.
63.
Starnes T, Robertson MJ, Sledge G, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001; 167: 4137.
64.
Prud’homme JG. Pathobiology of transforming growth factor b in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
65.
Shao S, Fang H, Duan L, et al. Lysyl hydroxylase 3 increases collagen deposition and promotes pulmonary fibrosis by activating TGF1/Smad3 and Wnt/-catenin pathways. Arch Med Sci 2019; 16: 436-45.
66.
Wang A, Wang F, Yin Y, Zhang M, Chen P. Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis. Artif Cells Nanomed Biotechnol 2018; 46: 783-7.
67.
Li Y, Jiang L, Zhang S, et al. Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int 2012; 32: 2415-22.
68.
Krasowska D, Rudnicka L, Dańczak-Pazdrowska A, et al. Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment. Dermatol Rev 2017; 104: 583-96.
69.
Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of IL-17 in inflammatory skin diseases. Br J Dermatol 2016; 175: 892-901.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
